Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.50 |
| ▸ | ITGAV | P06756 | 3/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.47 |
| ▸ | CHRNG | P07510 | 2/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.47 |
| ▸ | CHRND | Q07001 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121793 | 1.00 | ITGB3 (0.50) | ITGB3ITGAVITGA2BNOS2TYR | |
| SCHEMBL29542801 | 1.00 | ITGB3 (0.50) | ITGB3ITGAVITGA2BNOS2TYR | |
| SCHEMBL2925252 | 0.91 | NLRP3 (0.53) | CHRNA1CHRNGCHRNB1CHRNDACE | |
| SCHEMBL5085780 | 0.88 | CTSB (0.53) | ITGB3ITGAVITGA2BACEACE2 | |
| SCHEMBL9828876 | 0.88 | CTSB (0.53) | ITGB3ITGAVITGA2BACEACE2 | |
| SCHEMBL7758997 | 0.87 | ITGB3 (0.58) | ITGB3ITGA2BACEACE2CTSK | |
| SCHEMBL844471 | 0.87 | ITGB3 (0.58) | ITGB3ITGA2BACEACE2CTSK | |
| SCHEMBL2185240 | 0.87 | ITGB3 (0.58) | ITGB3ITGA2BACEACE2CTSK | |
| SCHEMBL5085119 | 0.87 | CTSK (0.50) | ITGB3ITGAVITGA2BACEACE2 | |
| SCHEMBL5500451 | 0.87 | CTSL (0.50) | ITGB3ITGAVITGA2BACEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004670-B1 | PROCESS FOR THE MANUFACTURE OF LYSOBACTIN DERIVATIVES | AICURIS GMBH & CO KG (DE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090163696-A1 | METHOD FOR PREPARING LYSOBACTIN DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163696-A1 | METHOD FOR PREPARING LYSOBACTIN DERIVATIVES | DLST, VIP, HAMP | ITGB3 4455/4885ITGAV 3737/4885ITGA2B 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.